MarketScreener Homepage > Equities > Swiss Exchange > Roche Holding AG ROG CH0012032048

Report

Delayed Swiss Exchange - 12/04 04:01:07 am
299.95	CHF		+0.08%

12/02

GLOBAL MARKETS LIVE: A flurry of acquisitions

12/02

ROCHE : Genentech Announces FDA Approval of Gavreto for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers

12/02

ROCHE : announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers

Summary

Quotes 5-day view Delayed Quote.

Delayed Swiss Exchange

11/30/2020	12/01/2020	12/02/2020	12/03/2020	12/04/2020	Date
299.05(c)	299.6(c)	302.65(c)	299.7(c)	299.95	Last
3 036 740	1 825 494	1 580 896	2 283 830	169 859	Volume
-1.14%	+0.18%	+1.02%	-0.97%	+0.08%	Change

More quotes

Financials

Sales 2020	59 925 M 67 284 M 67 284 M
Net income 2020	14 348 M 16 110 M 16 110 M
Net cash position 2020	3 429 M 3 850 M 3 850 M
P/E ratio 2020	18,2x
Yield 2020	3,10%

Sales 2021	62 876 M 70 598 M 70 598 M
Net income 2021	15 592 M 17 507 M 17 507 M
Net cash position 2021	11 577 M 12 999 M 12 999 M
P/E ratio 2021	16,5x
Yield 2021	3,20%

Capitalization	256 B 288 B 288 B
EV / Sales 2020	4,22x
EV / Sales 2021	3,89x
Nbr of Employees	97 735
Free-Float	83,6%

More Financials

Company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The...

Sector

Pharmaceuticals

Calendar

12/03

Presentation

More about the company

Notations Surperformance© of Roche Holding AG

Trading Rating :

Investor Rating :

More Ratings

All news about ROCHE HOLDING AG

12/02	GLOBAL MARKETS LIVE: A flurry of acquisitions
12/02	ROCHE : Genentech Announces FDA Approval of Gavreto for People With Advanced or ..	AQ
12/02	ROCHE : announces FDA approval of Gavreto (pralsetinib) for people with advanced..	AQ
12/02	ROCHE : receives FDA Emergency Use Authorization for new test to measure the lev..	AQ
12/01	Blueprint Medicines Says FDA Approves Gavreto to Treat Thyroid Cancer	DJ
12/01	GENENTECH : Announces FDA Approval of Gavreto (pralsetinib) for People With Adva..	BU
12/01	NOVARTIS : Genentech Get Expanded FDA OK of Xolair for Nasal Polyps	DJ
12/01	ROCHE : FDA approves Xolair® (omalizumab) for adults with nasal polyps	AQ
12/01	ROCHE : Gets FDA Emergency Use OK for Test to Measure Level of SARS-CoV-2 Antibo..	DJ
12/01	GENENTECH : Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal ..	BU
12/01	GLOBAL MARKETS LIVE: Bank of America, Pfizer, Tesla…
12/01	REMINDER : Invitation to Roche's virtual event on key hematology data presented ..	PU
11/30	Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules	AQ
11/29	Swiss firms narrowly avoid 'Responsible Business' liability as vote divides n..	RE
11/26	Business rights or human rights? Swiss vote shines spotlight on companies	RE

More news

News in other languages on ROCHE HOLDING AG

12/03	Aktien Schweiz schließen den vierten Tag in Folge schwächer
12/02	Aktien Schweiz schließen wenig verändert - Pharmaaktien fest
12/02	ROCHE : approbation de la FDA en cancer de la thyroïde
12/02	ROCHE : autorisation d'Elecsys Anti-SARS-CoV-2 S par la FDA
12/02	EN DIRECT DES MARCHES : Alstom, Total, Peugeot, Lumibird, Interparfums, Salesfor..

More news

Analyst Recommendations on ROCHE HOLDING AG

11/10	ROCHE HOLDINGS AG : UBS gives a Buy rating	MD
11/05	ROCHE HOLDINGS AG : Buy rating from JP Morgan	MD
10/29	ROCHE HOLDINGS AG : UBS keeps its Buy rating	MD

More recommendations

Stock Trading Strategies

	ROCHE HOLDING AG - 08/19
Close to an important medium term support level

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

Swiss firms narrowly avoid 'Responsible Business' liability as vote divides nation